Therefore, the inhibition of SGLT2 and partial inhibition of SGLT1 can increase urinary glucose excrement, inhibit gastrointestinal glucose absorption and better control of blood glucose without increasing serious adverse reactions, thus becoming a new hope for the treatment of T2DM. This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.